| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 33.2 | 22.2 | 25.5 |
| Other income | 0.1 | 0.0 | 0.1 |
| Total income | 33.3 | 22.2 | 25.6 |
| Profit before exceptional items & tax | 1.5 | 0.8 | 1.4 |
| Exceptional items | 0.1 | 0.3 | 0.0 |
| Profit before tax | 1.6 | 1.0 | 1.4 |
| Net profit | 1.3 | 0.8 | 0.9 |
| Operating margin | 4.8% | 4.5% | 5.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +44.40% |
|---|---|
| Net profit, quarter on quarter | +62.50% |
| Revenue, year on year | +30.20% |
BSE results filing, NSE: GODAVARI. Figures extracted from the filing.
Godavari Drugs Ltd: key numbers
- Share price
- ₹123.80
- Market cap
- ₹125.4 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹4.09 Cr
- P/E (TTM)
- 30.1×Sector 47.4×
- Promoter holding
- 40.23%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Godavari Drugs Ltd
All →Godavari Drugs Annual General Meeting
Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.
Godavari Drugs Annual General Meeting
Godavari Drugs Limited will close its register of members and share transfer books from September 19 to September 25, 2026, for its 38th Annual General Meeting.
Godavari Drugs Board Meeting Outcome
Godavari Drugs approved altering its Memorandum of Association to add a nutraceuticals business object. A revised notice for the 38th AGM was also approved.
Godavari Drugs Capital Structure Change
Godavari Drugs Limited allotted 7,86,690 equity shares to the promoter category following warrant conversion. The company received Rs. 5.25 Crore, representing the final 75% payment.
- Value
- ₹5.25 Cr
Godavari Drugs Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 10.0% YoY
Godavari Drugs Ltd reported revenue from operations of ₹28 Cr (+17.6% YoY) and net profit of ₹1.1 Cr (+10.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · +10.0% YoY
Godavari Drugs Board Meeting Date
Godavari Drugs Limited has scheduled a board meeting for August 24, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.